The consensus question is 'when does the GLP-1 drug lose its patent?' — as if there's one patent and one date. The 2024 filings say that framing is wrong, and the distinction is where the real money sits.
Here's the single fact that complicates the cliff: a peptide drug isn't protected by one patent. It's protected by the molecule, plus the formulation, plus the dosing regimen, plus — increasingly — the delivery device or oral-delivery chemistry. Each is separately patented and separately dated.
Oral delivery is the hot frontier, because making a fragile peptide survive the gut is genuinely hard and genuinely patentable. Publication US20240173262A1 covers a mucoadhesive dosage form for unidirectional release of peptide particles — a formulation invention, not a molecule. Solve oral delivery and you've created fresh exclusivity on an old drug.
Composition claims do the same work. Novo Nordisk's co-agonist grant US12054528B2 covers a new molecule, but the broader pattern is that companies layer new compositions over aging cores to keep the protected version current.
Acknowledge the bull-for-generics case: when the core molecule's protection lapses, biosimilar and generic peptide makers can copy it, and formulation patents don't stop a competitor from using a different formulation. The cliff is real.
But the Cliff Watch read is that the cliff is jagged, not a single drop. The molecule may expire while the oral formulation patients actually use is still protected for years. So the honest answer to 'when's the cliff?' is: which patent, on which version, are you asking about? In 2024 the action moved to formulation — and that's where the real expiry fight will be fought.